淋巴结阳性乳腺癌患者接受区域淋巴结照射的多束调强放疗可行性研究的长期肺部结局
2010年7月至2013年1月入组113例淋巴结阳性乳腺癌患者,接受逆向计划多束调强放疗照射乳腺/胸壁及区域淋巴结(含内乳淋巴结),中位随访53.4个月,104例完成随访。中位肺V20Gy为29%、V5为100%,≥3级放射性肺炎发生率为0.96%(1/104),调强放疗后肺功能测试及社区获得性肺炎评分无差异。
要点
- 中位随访53.4个月,104例可评估患者中≥3级放射性肺炎仅1例(0.96%)。
- 中位肺V20Gy为29%、V5为100%,低剂量受照肺体积大但≥3级放射性肺炎发生率低。
- 调强放疗后肺功能测试与社区获得性肺炎评分较基线无差异。
核心结论
- 基于早期治疗计划标准,区域淋巴结照射的多束调强放疗在剂量学上可行,尽管低剂量受照肺体积大,≥3级放射性肺炎发生率仍很低,作者认为这支持将逆向计划调强放疗用于常规放疗技术不充分的高危乳腺癌患者。
研究设计与样本
- 2010年7月至2013年1月开展的前瞻性可行性研究,入组113例淋巴结阳性乳腺癌患者,接受逆向计划多束调强放疗照射乳腺或胸壁及区域淋巴结(含内乳淋巴结)。
- 主要终点为可行性,由剂量学治疗计划标准预先定义;次要终点包括≥3级放射性肺炎发生率及基线至调强放疗后6个月的肺功能变化。
- 临床随访每6个月一次,最长5年;中位随访53.4个月(范围0-82个月),113例入组患者中104例完成随访程序。
主要发现
- 乳腺或胸壁及内乳淋巴结覆盖充分,中位剂量分别为48.1 Gy和48.9 Gy。
- 肺高剂量受照体积中位V20Gy为29%,低剂量受照体积中位V5为100%。
- 总体呼吸系统毒性发生率为10.6%(11/104),其中≥3级放射性肺炎1例(0.96%)。
- 调强放疗后肺功能测试及社区获得性肺炎评分未见差异。
- 5年局部区域无复发生存率、无病生存率和总生存率分别为93.2%、63.6%和80.3%。
关键数值与推荐
- 可行性由剂量学治疗计划标准预先定义,原文未列出具体标准条款。
- ≥3级放射性肺炎发生率0.96%(1/104)。
- 中位乳腺或胸壁剂量48.1 Gy,中位内乳淋巴结剂量48.9 Gy。
- 中位肺V20Gy为29%,中位肺V5为100%。
临床怎么用
- 作者认为,对于常规放疗技术不充分的髙危乳腺癌患者,逆向计划调强放疗可作为治疗方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multibeam intensity modulated radiation therapy (IMRT) enhances the therapeutic index by increasing the dosimetric coverage of the targeted tumor tissues while minimizing volumes of adjacent organs receiving high doses of RT. The tradeoff is that a greater volume of lung is exposed to low doses of RT, raising concern about the risk of radiation pneumonitis (RP). METHODS AND MATERIALS: Between July 2010 and January 2013, patients with node-positive breast cancer received inverse-planned, multibeam IMRT to the breast or chest wall and regional nodes, including the internal mammary nodes (IMNs). The primary endpoint was feasibility, predefined by dosimetric treatment planning criteria. Secondary endpoints included the incidence of RP grade 3 or greater and changes in pulmonary function measured with the Common Terminology Criteria for Adverse Events version 3.0 scales, pulmonary function tests and community-acquired pneumonia questionnaires, obtained at baseline and 6 months after IMRT. Clinical follow-up was every 6 months for up to 5 years. RESULTS: Median follow-up was 53.4 months (range, 0-82 months). Of 113 patients enrolled, 104 completed follow-up procedures. Coverage of the breast or chest wall and IMN was comprehensive (median 48.1 Gy and 48.9 Gy, respectively). The median volume of lung receiving a high dose (V20Gy) and a low dose (V5) was 29% and 100%, respectively. The overall rate of respiratory toxicities was 10.6% (11/104), including 1 grade 3 RP event (0.96%). No differences were found in pulmonary function test or community-acquired pneumonia scores after IMRT. The 5-year rates of locoregional recurrence-free, disease-free, and overall survival were 93.2%, 63.6%, and 80.3%, respectively. CONCLUSIONS: Multibeam IMRT in patients with breast cancer receiving regional nodal irradiation was dosimetrically feasible, based on early treatment planning criteria. Despite the large volume of lung receiving low-dose RT, the incidence of grade 3 RP was remarkably low, justifying inverse-planned IMRT as a treatment modality for patients with high-risk breast cancer in whom conventional RT techniques prove inadequate.
引用
- Ho AY, Ballangrud A, Li G, et al. Long-Term Pulmonary Outcomes of a Feasibility Study of Inverse-Planned, Multibeam Intensity Modulated Radiation Therapy in Node-Positive Breast Cancer Patients Receiving Regional Nodal Irradiation. Int J Radiat Oncol Biol Phys. 2018. PMID: 30508620. doi:10.1016/j.ijrobp.2018.11.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。